243 related articles for article (PubMed ID: 33102599)
1. Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.
Yao D; Xu L; Liu L; Zeng X; Zhong J; Lai J; Zheng R; Jin Z; Chen S; Zha X; Huang X; Lu Y
Biomed Res Int; 2020; 2020():9531549. PubMed ID: 33102599
[TBL] [Abstract][Full Text] [Related]
2. Terminal differentiation of bone marrow NK cells and increased circulation of TIGIT
Zeng X; Yao D; Liu L; Zhang Y; Lai J; Zhong J; Zha X; Lu Y; Jin Z; Chen S; Li Y; Xu L
Asia Pac J Clin Oncol; 2022 Aug; 18(4):456-464. PubMed ID: 34811925
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment.
Yao D; Lai J; Lu Y; Zhong J; Zha X; Huang X; Liu L; Zeng X; Chen S; Weng J; Du X; Li Y; Xu L
Front Immunol; 2023; 14():1078118. PubMed ID: 36742315
[TBL] [Abstract][Full Text] [Related]
4. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
5. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
Lanza F; Bi S; Castoldi G; Goldman JM
Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
Watanabe N; Takaku T; Takeda K; Shirane S; Toyota T; Koike M; Noguchi M; Hirano T; Fujiwara H; Komatsu N
Int J Hematol; 2018 Dec; 108(6):588-597. PubMed ID: 30151740
[TBL] [Abstract][Full Text] [Related]
7. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.
García-Sanz R; González M; Orfão A; Moro MJ; Hernández JM; Borrego D; Carnero M; Casanova F; Bárez A; Jiménez R; Portero JA; San Miguel JF
Br J Haematol; 1996 Apr; 93(1):81-8. PubMed ID: 8611480
[TBL] [Abstract][Full Text] [Related]
8. [Interferon-α mediating the functional damage of CD56
Zhao XG; Liu JQ; Huang HN; Lu ZM; Bai ZR; Li X; Qi JJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):975-981. PubMed ID: 38101777
[TBL] [Abstract][Full Text] [Related]
9. Effect of the in vivo application of granulocyte colony-stimulating factor on NK cells in bone marrow and peripheral blood.
Yu XX; Han TT; Xu LL; Chang YJ; Huang XJ; Zhao XY
J Cell Mol Med; 2018 Jun; 22(6):3025-3034. PubMed ID: 29575692
[TBL] [Abstract][Full Text] [Related]
10. Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.
Vidriales MB; Orfao A; López-Berges MC; González M; Hernandez JM; Ciudad J; López A; Moro MJ; Martínez M; San Miguel JF
Ann Hematol; 1993 Nov; 67(5):217-22. PubMed ID: 7694663
[TBL] [Abstract][Full Text] [Related]
11. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML.
Brauneck F; Seubert E; Wellbrock J; Schulze Zur Wiesch J; Duan Y; Magnus T; Bokemeyer C; Koch-Nolte F; Menzel S; Fiedler W
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884723
[TBL] [Abstract][Full Text] [Related]
12. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
13. Skewed distribution of natural killer cells in psoriasis skin lesions.
Batista MD; Ho EL; Kuebler PJ; Milush JM; Lanier LL; Kallas EG; York VA; Chang D; Liao W; Unemori P; Leslie KS; Maurer T; Nixon DF
Exp Dermatol; 2013 Jan; 22(1):64-6. PubMed ID: 23278897
[TBL] [Abstract][Full Text] [Related]
14. Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow.
Park M; Park CJ; Cho YW; Jang S; Lee JH; Lee JH; Lee KH; Lee YH
Exp Hematol; 2017 Jan; 45():56-63. PubMed ID: 27693387
[TBL] [Abstract][Full Text] [Related]
15. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.
Brück O; Blom S; Dufva O; Turkki R; Chheda H; Ribeiro A; Kovanen P; Aittokallio T; Koskenvesa P; Kallioniemi O; Porkka K; Pellinen T; Mustjoki S
Leukemia; 2018 Jul; 32(7):1643-1656. PubMed ID: 29925907
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion.
Herrera Lara S; Fernández-Fabrellas E; Juan Samper G; Marco Buades J; Andreu Lapiedra R; Pinilla Moreno A; Morales Suárez-Varela M
Lung; 2019 Feb; 197(1):53-60. PubMed ID: 30523401
[TBL] [Abstract][Full Text] [Related]
17. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis.
Lima M; Almeida J; Montero AG; Teixeira Mdos A; Queirós ML; Santos AH; Balanzategui A; Estevinho A; Algueró Mdel C; Barcena P; Fonseca S; Amorim ML; Cabeda JM; Pinho L; Gonzalez M; San Miguel J; Justiça B; Orfão A
Am J Pathol; 2004 Oct; 165(4):1117-27. PubMed ID: 15466379
[TBL] [Abstract][Full Text] [Related]
18. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
[TBL] [Abstract][Full Text] [Related]
19. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.
Lopez-Vergès S; Milush JM; Pandey S; York VA; Arakawa-Hoyt J; Pircher H; Norris PJ; Nixon DF; Lanier LL
Blood; 2010 Nov; 116(19):3865-74. PubMed ID: 20733159
[TBL] [Abstract][Full Text] [Related]
20. NK cells dysfunction in systemic lupus erythematosus: relation to disease activity.
Henriques A; Teixeira L; Inês L; Carvalheiro T; Gonçalves A; Martinho A; Pais ML; da Silva JA; Paiva A
Clin Rheumatol; 2013 Jun; 32(6):805-13. PubMed ID: 23377197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
